Drug-Induced Xenogenization (DIX) and Pharmacological Control of Tumor-associated Antigen Expression
A special issue of Scientia Pharmaceutica (ISSN 2218-0532).
Deadline for manuscript submissions: closed (30 May 2020) | Viewed by 304
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, tumor immunotherapy has received an extraordinary impulse from the discovery and clinical application of immune checkpoint inhibitors. However, the success of immunotherapy, which in most cases relies on the presence of tumor neoantigens, is still limited. In 1970, we discovered that in vivo treatment of leukemia-bearing mice with triazene compounds was able to convert non-immunogenic leukemia cells into highly immunogenic blasts. This phenomenon that we called drug-induced xenogenization (DIX) is the result of triazene-induced somatic mutations generating MHC-associated nonself peptides. This discovery, along with more recent findings showing that several drugs are able to modulate the immunogenic properties of tumors, appears to pave the way for a novel immunotherapeutic approach of malignant diseases, i.e., the pharmacological control of tumor immunogenicity.
This Special Issue is dedicated to gathering as much information as possible on different drugs able to increase the amount and strength of tumor associated antigens.
Prof. Enzo Bonmassar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Scientia Pharmaceutica is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Xenogenization
- Tumor immunotherapy
- Tumor neoantigens
- Antigen expression modulation
- Tumor-associated antigens
- Drug-induced antigen remodeling
- Tumor immunogenicity
- Triazenes
- DIX
- Drug-induced mutation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
